Material and methods for treating or preventing HER-3 associated diseases
AssigneesAmgen Inc., Daiichi Sankyo Europe GmbH
InventorsThore Hettmann, Daniel J. Freeman, Robert Radinsky
Life of this patent
Estimating the term…
Abstract
Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
Claims38
A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an isolated binding protein which binds to HER-3,- comprising:
- (a) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:
- 236, a CDRH2 having the sequence of SEQ ID NO:
- 258, and a CDRH3 having the sequence of SEQ ID NO:
- 283;
- and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:
- 320, a CDRL2 having the sequence of SEQ ID NO:
- 343, and a CDRL3 having the sequence of SEQ ID NO:
- 360;
- (b) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:
- 236, a CDRH2 having the sequence of SEQ ID NO:
- 258, and a CDRH3 having the sequence of SEQ ID NO:
- 285;
- and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID No:
- 320, a CDRL2 having the sequence of SEQ ID NO:
- 343, and a CDRL3 having the sequence of SEQ ID NO:
- 360;
- (c) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:
- 251, a CDRH2 having the sequence of SEQ ID NO:
- 278, and a CDRH3 having the sequence of SEQ ID NO:
- 309;
- and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:
- 334, a CDRL2 having the sequence of SEQ ID NO:
- 356, and a CDRL3 having the sequence of SEQ ID NO:
- 381;
- (d) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:
- 252, a CDRH2 having the sequence of SEQ ID NO:
- 280, and a CDRH3 having the sequence of SEQ ID NO:
- 313;
- and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:
- 337, a CDRL2 having the sequence of SEQ ID NO:
- 351, and a CDRL3 having the sequence of SEQ ID NO:
- 385;
- or
- (e) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:
- 256, a CDRH2 having the sequence of SEQ ID NO:
- 282, and a CDRH3 having the sequence of SEQ ID NO:
- 315;
- and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:
- 340, a CDRL2 having the sequence of SEQ ID NO:
- 344, and a CDRL3 having the sequence of SEQ ID NO:387;
- and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.
A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3 and comprises the heavy chain amino acid sequence of SEQ ID NO:
- 42 and the light chain amino acid sequence of SEQ ID NO:
- 44, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.
A method of treating a cancer associated with HER-3 in a subject comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3, and comprises a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 42, 54, 70, 92, and 96, and a light chain, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.
A method of treating a cancer associated with HER-3 in a subject comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises a light chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 44, 56, 72, 94, and 98, and a heavy chain, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.
A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3 and comprises the heavy chain amino acid sequence of SEQ ID NO:
- 70 and the light chain amino acid sequence of SEQ ID NO:
- 72, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.
Dependencies are inferred from the claim text.